Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.
about
From Structure-Function Analyses to Protein Engineering for Practical Applications of DNA LigasePrevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionSimplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide LigationIntrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencingMinority variants of drug-resistant HIV.Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineOligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1.Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysisNevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype CA comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru.Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesOne-Step Ligation on RNA Amplification for the Detection of Point MutationsEvaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus.Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay.Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.Genotypic resistance testing in HIV by arrayed primer extension.Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene.Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.SMARThivPack: a complexity free and cost effective "three tests" combo kit model for improving HIV patients monitoring standards in resource poor settings.Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.Implementation of a point mutation assay for HIV drug resistance testing in Kenya
P2860
Q26778289-B3D0D598-145F-4BA5-B9DB-42EE6A240F48Q28478459-2CAD0ADC-AEB0-4BF5-9D6C-15DADF2997D1Q28552499-5AA1C251-4B16-48D3-B627-0D16D21BCAF3Q33686931-D9B218EE-EA6A-4A81-BB40-7BF18778AB18Q33899918-E1FC702A-00D4-433A-9791-1E8133073776Q34047780-F4665425-B41D-4046-9502-9242015481E0Q34071112-E374C311-07FF-4000-BE6F-C38FD9D2D6E1Q34073276-D1D7532F-2F49-4A37-8552-787EBC4A1F7AQ34339340-EF0D1235-CE00-4281-B1F5-438B7B54F132Q34528801-E11F1C52-6CA8-4F22-A51F-629C4D71C829Q34572571-8C9C9314-0768-4FE0-9468-093824572C70Q35187157-43DDFE53-E05E-41C3-85AB-549B9641B67CQ35632898-3D21AE48-DC47-4402-8D9D-676436EEFB82Q35862295-E9AE2D47-E459-425A-A48E-E56E034E5C5DQ35947480-EA0E77E3-59B8-40EF-81C2-C7F6B80DC717Q36240649-6F5C75E0-1475-4156-A88D-D9DBCA512228Q36783609-A1C53310-0C78-4544-ABB9-3ADDF4A49444Q36814047-501E574C-4478-4B3C-BA90-D18CC1CC82ACQ36845456-F473E4A7-9A6B-4508-9865-A9CECC38D6B0Q36973809-1B12919F-AED6-489B-B612-6446EF7B40B7Q37003038-C40C71B0-5A90-4544-8396-04112A0EFCCEQ37156918-38C780E2-CDFE-4770-90F5-1BEA66068EE9Q37357573-3BC083B4-4861-4872-A36B-E45D1038F0C5Q39627213-F807C46A-B8A2-4869-B1F3-C07F2FF41A47Q39748924-FF89FFCB-3539-465C-A8BC-57F292BDA208Q41761525-FD3C921B-2F7D-4DA0-B834-9401CCDE2003Q42532506-69174C6D-3115-42A3-9096-3A9ABC5ECEB3Q43053081-17BF1F04-2885-4123-A507-D383D6FBD07AQ45326210-7FA04D90-15AE-43CC-B603-57FFEA69F1E0Q47609679-366D06D3-92CB-426E-92BA-07C92D7AFB52Q57131360-79748382-D158-4480-A030-05F20BEB721E
P2860
Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@ast
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@en
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@nl
type
label
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@ast
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@en
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@nl
prefLabel
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@ast
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@en
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@nl
P2093
P2860
P1476
Rapid and sensitive oligonucle ...... stance to protease inhibitors.
@en
P2093
Amy Wright
Erika Langston
Gregory Pepper
Ingrid A Beck
Lisa M Frenkel
Madhumita Mahalanabis
Shannon Hamilton
P2860
P304
P356
10.1128/JCM.40.4.1413-1419.2002
P407
P577
2002-04-01T00:00:00Z